Establishment and Characterization of Multi-Drug Resistant p53-Negative Osteosarcoma SaOS-2 Subline
Aim: To establish a p53-negative osteosarcoma (OS) SaOS-2 cellular subline exhibiting resistance to specific chemotherapeutic agents, including topoisomerase II inhibitors, taxanes, and vinca alkaloids. Methods: The OS subline exhibiting resistance to the chemotherapeutic agents indicated above was...
Main Authors: | Sergei Boichuk, Firyuza Bikinieva, Elena Valeeva, Pavel Dunaev, Maria Vasileva, Pavel Kopnin, Ekaterina Mikheeva, Tatyana Ivoilova, Ilshat Mustafin, Aigul Galembikova |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-08-01
|
Series: | Diagnostics |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4418/13/16/2646 |
Similar Items
-
Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells
by: Sergei Boichuk, et al.
Published: (2022-03-01) -
Black phosphorus quantum dots camouflaged with platelet-osteosarcoma hybrid membrane and doxorubicin for combined therapy of osteosarcoma
by: Yanlong Xu, et al.
Published: (2023-07-01) -
Unraveling the Mechanisms of Sensitivity to Anti-FGF Therapies in Imatinib-Resistant Gastrointestinal Stromal Tumors (GIST) Lacking Secondary <i>KIT</i> Mutations
by: Sergei Boichuk, et al.
Published: (2023-11-01) -
Doxorubicin Dose Deintensification in Pediatric Osteosarcoma, Is Less Better?
by: Hadeel Halalsheh, et al.
Published: (2023-07-01) -
Chitosan-Boric Acid Scaffolds for Doxorubicin Delivery in the Osteosarcoma Treatment
by: Luka Dornjak, et al.
Published: (2022-11-01)